Rivaroxaban, an oral direct factor Xa inhibitor

By Piccini Jonathan P   Patel Manesh R   Mahaffey Kenneth W   Fox Keith AA   Califf Robert M  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 925-937

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor

By  

Current Clinical Pharmacology, Vol. 9, Iss. 1, 2014-02 ,pp. : 75-83

Bentham Science Publishers

Access to resources Recommend Favorite

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - in Patients Undergoing Major Orthopaedic Surgery

By Mueck Wolfgang  

Clinical Pharmacokinetics, Vol. 47, Iss. 3, 2008-01 ,pp. : 203-216

Adis International

Access to resources Recommend Favorite

Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty

By Borris Lars C  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 6, 2009-04 ,pp. : 1083-1088

Informa Healthcare

Access to resources Recommend Favorite

Absence of Clinically Relevant Interactions between Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – and Digoxin or Atorvastatin in Healthy Subjects

By Kubitza D   Becka M   Roth A   Mueck W  

The Journal of International Medical Research, Vol. 40, Iss. 5, 2012-09 ,pp. : 1688-1707

Field House Publishing

Access to resources Recommend Favorite